Answers are grounded in this paper and cite their sources.
Post-marketing surveillance reveals Fluticasone Furoate effectively manages asthma symptoms in Japan, suggesting good safety profile with ADRs under 10%.
FF/UMEC/VI was well tolerated and effective in the treatment of patients with asthma in Japan. ADRs were reported in 8.4% of patients and the incidence of CV events was low. No new safety concerns were identified.
No takes yet. Share an insight, caveat, or question.
Morioka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: